Stem cell therapy of COVID-19 & respiratory diseases

  1. Home
  2. Stem cell therapy of COVID-19 & respiratory diseases

Pulmonary diseases are the leading cause of death globally. Chronic obstructive pulmonary disease (COPD) alone is the top third-ranked killer, followed by lower respiratory infections. COVID-19 pandemic and other critically respiratory infections claim millions of lives annually. Most respiratory diseases, including COPD, lung cancer, idiopathic pulmonary fibrosis, asthma, and acute respiratory distress syndrome (ARDS), are refractory illnesses.

Stem cell therapy holds the most promising to regenerate functional “new” lungs. Very recently, considerable progress has been reported in the physiology, pathology, and biology of respiratory stem cells. 

Various article types are welcomed, including research, commentary, letter, method, review, short report, and viewpoint. Before submitting your manuscript, please ensure you have carefully read our submission guidelines for JSR.

All manuscripts should be submitted to the

Read the published articles here